Open Access This article is
- freely available
Molecules 2017, 22(4), 651; https://doi.org/10.3390/molecules22040651
Antifungal and Anti-Biofilm Activities of Acetone Lichen Extracts against Candida albicans
Laboratoire de Chimie des Substances Naturelles, Faculté de Pharmacie, 2 rue du Dr Marcland, 87025 Limoges, France
Laboratoire Ecologie et Biologie des Interactions, Equipe Microbiologie de l’Eau, Université de Poitiers, UMR CNRS 7267, F-86073 Poitiers, France
Correspondence: [email protected]; Tel.: +33-05-55-43-58-35
These authors contributed equally to this work.
Academic Editors: Sophie Tomasi and Joel Boustie
Received: 20 February 2017 / Accepted: 14 April 2017 / Published: 19 April 2017
Candida albicans is a commensal coloniser of the human gastrointestinal tract and an opportunistic pathogen, especially thanks to its capacity to form biofilms. This lifestyle is frequently involved in infections and increases the yeast resistance to antimicrobials and immune defenses. In this context, 38 lichen acetone extracts have been prepared and evaluated for their activity against C. albicans planktonic and sessile cells. Minimum inhibitory concentrations of extracts (MICs) were determined using the broth microdilution method. Anti-biofilm activity was evaluated using tetrazolium salt (XTT) assay as the ability to inhibit the maturation phase (anti-maturation) or to eradicate a preformed 24 h old biofilm (anti-biofilm). While none of the extracts were active against planktonic cells, biofilm maturation was limited by 11 of the tested extracts. Seven extracts displayed both anti-maturation and anti-biofilm activities (half maximal inhibitory concentrations IC50_mat and IC50_biof ≤ 100 µg/mL); Evernia prunastri and Ramalina fastigiata were the most promising lichens (IC50_mat < 4 µg/mL and IC50_biof < 10 µg/mL). Chemical profiles of the active extracts performed by thin layer chromatography (TLC) and high performance liquid chromatography (HPLC) have been analyzed. Depsides, which were present in large amounts in the most active extracts, could be involved in anti-biofilm activities. This work confirmed that lichens represent a reservoir of compounds with anti-biofilm potential.
Keywords:lichens; biofilm; Candida albicans; screening; chemical profiling
Lichens are symbiotic organisms resulting from the association between a fungus, called the mycobiont (usually an ascomycete), and photoautotrophic partners, green algae, and/or cyanobacteria, called the photobiont. Recently, a third partner embedded in the lichen cortex was identified as a basidiomycete yeast . The lichen thallus is a support for other microorganisms living inside and outside the thallus, including endo- and epi-lichenic fungi and bacteria [2,3]. Interactions exist within this complex ecosystem and many of the molecules that make up this chemical environment are involved in interactions between the community members influencing overall community homeostasis and survival. This complex community is a potential source of new pharmaceutical drugs [4,5].
Candida spp. belongs to the healthy human microbiota and Candida albicans is a normal inhabitant of the gastrointestinal tract, reproductive tract, oral cavity, and skin of most humans [6,7]. C. albicans is also an opportunistic yeast causing superficial and invasive infections, especially among elderly and/or frail patients (immunocompromised, with long term stays in intensive care units, after digestive surgery, etc.) [8,9,10]. Oral candidiasis is a common superficial and opportunistic infection accounting for significant morbidity, especially in immunocompromised patients and, more generally, in denture wearers [11,12,13]. Biofilms may form on a variety of surfaces, with catheter, dental, and mucosal surfaces being the most common. Adherence of Candida yeasts to these host surfaces is a prerequisite for subsequent colonization and biofilm formation [14,15,16] and, therefore, is a key step in the process leading to oral candidiasis. The adhesion phase is followed by the maturation of the biofilm, characterized by hyphae and extracellular matrix production . Biofilm formation is implicated in 80% of infections, and is an important virulence factor as sessile cells become poorly or not susceptible to both antimicrobials and host immune responses .
Natural compounds, such as polyphenols, have begun to be tested against biofilms. Good activities have been described for curcumin and pyrogallol against C. albicans biofilm . Purpurin, a natural anthraquinone pigment, has demonstrated an effect against C. albicans hyphal formation and biofilm development . Lichen extracts and their metabolites have been widely studied for their antimicrobial properties, but their anti-biofilm potential is still poorly explored. Mitrovic et al. have studied the anti-biofilm activity of two common lichens (Platismatia glauca and Pseudevernia furfuracea) against S. aureus biofilms. The acetone, ethyl acetate or methanol extracts showed activities with a biofilm inhibitory concentration (BIC) ranging from 0.63 mg/mL to 1.25 mg/mL . While few lichen metabolites have been evaluated against C. albicans biofilms, no lichen extracts have been tested for such an activity. Chang et al. have demonstrated the anti-biofilm activity of retigeric acid B, a pentacyclic triterpenoid isolated from the lichen Lobaria kurokawae, by inhibiting C. albicans yeast-to-hypha transition in infected mice and by acting synergistically with azoles to block C. albicans biofilm formation .
Thus, lichens appear to be a non-negligible source of bacterial or fungal anti-biofilm compounds. In this study, a screening of 38 acetone extracts, obtained from lichens mostly collected in Limousin (France), was performed against planktonic and sessile C. albicans cells. Lichens selected for this work belonged to nine different families (Parmeliaceae and Cladoniaceae, principally). Samples have been collected on trees, rocks, or soil, implying variations on their ecological environment (insects, herbivores, fungi, bacteria). Their anti-biofilm activities, as well as their chemical composition, were investigated.
The aim of this study was, thus, to investigate lichens from the center-west of France as new natural sources for anti-biofilm agents and, in particular, to search for lichen extracts able to both inhibit the maturation of C. albicans biofilms (suggesting a prophylactic interest) and reduce an already formed biofilm of C. albicans (suggesting a curative interest).
2. Results and Discussion
2.1. Preparation of Extracts
Extracts were obtained by the maceration of the lichen thallus in acetone, at room temperature. This extraction protocol led to good extraction rates, ranging between 0.2% and 10.5% for the majority of lichens (see Table 1), and to a wide diversity of secondary metabolites (terpenes, sterols, depsidones, depsides, dibenzofurans, xanthones). Furthermore, the extraction of primary metabolites, such as sugars, as well as thermal degradation of thermolabile compounds (depsides or diphenylethers) were limited.
Extracts have been analyzed by thin layer chromatography (TLC) in two system solvents and observed under ultraviolet (UV) and after spraying anisaldehyde sulfuric reagent and/or by high performance liquid chromatography (HPLC). A comparison with standards and bibliographic data allowed the identification of major compounds in almost all extracts [23,24,25]. Polyphenolic compounds (depsides, depsidones, dibenzofurans, and xanthones) and terpenoids predominated in the chemical profiles of the studied lichen extracts, with often one or two major metabolites (Table 1 and Supplemental Figure S1).
2.2. Antifungal Activity
The 38 lichen extracts were first evaluated for their activity against C. albicans planktonic yeast. None of the extracts displayed antifungal activity against these cells with minimal inhibitory concentrations (MICs) > 100 µg/mL (fluconazole MIC: 4 µg/mL). These results are consistent with data reported in the literature, which suggest poor activities of some lichen extracts and their compounds against planktonic microbes, and especially towards C. albicans, with MICs being often above 500 µg/mL [21,26,27].
2.3. Activity against Biofilm Maturation
Extracts were then tested against the growth of C. albicans biofilms on polystyrene substrates (anti-maturation activity) by incubating with very young biofilms (2 h adhered cells) for 24 h or 48 h. The half maximal inhibitory concentrations (IC50) of the extracts are presented in Table 2. Eleven extracts significantly inhibited biofilm growth onto polystyrene surfaces (1.5 µg/mL ≤ IC50_mat 48h ≤ 100 µg/mL; p < 0.03) after a 48 h incubation, suggesting their ability to delay biofilm maturation.
Four extracts (Anaptychia ciliaris, Cetraria islandica, Peltigera rufescens, and Xanthoria parietina) were not promising as anti-maturation agents due to the lack of activity at 24 h and their low activity at 48 h and were not selected for further investigations.
Among the active extracts, only four (Evernia prunastri, Peltigera hymenina, Ramalina fastigiata, and Xanthoparmelia conspersa) were active after both 24 h and 48 h incubation time, but the IC50 obtained after 24 h were always higher (25 µg/mL ≤ IC50_mat 24h ≤ 100 µg/mL) than those observed after 48 h (1.5 µg/mL ≤ IC50_mat 48h ≤ 25 µg/mL). This observation suggests that an extended contact between extracts and microbes is needed to obtain overall inhibitory activity. Additionally, it also suggests that these extracts could be promising for long-term prophylactic action. It is noteworthy that E. prunastri and R. fastigiata were the most active extracts against maturation phase, with IC50_mat 24h = 25 µg/mL and IC50_mat 48h ≤ 3.1 µg/mL.
2.4. Anti-Biofilm Activity
Lichen extracts which demonstrated an anti-maturation activity with IC50_mat 48h ≤ 50 µg/mL have been selected and tested against a pre-formed C. albicans biofilm 24 h of age by incubation for 48 h (according to the previous observation with anti-maturation tests), to evaluate their interest for a curative approach. Two complementary methods were used, tetrazolium salt (XTT) assay and colony-forming unit (CFU) counts. The IC50 and percentage of inhibition of the extracts are presented in Table 2. The seven tested extracts demonstrated significant anti-biofilm activity (≤10 µg/mL ≤ IC50_biof ≤ 100 µg/mL; p < 0.0002).
Four extracts, C. uncialis, E. prunastri, R. fastigiata, and X. conspersa showed the highest activity with IC50_biof ≤ 10 µg/mL. CFU counts confirmed this anti-biofilm activity by demonstrating a significant decrease in the yeast community constituting the biofilm (inhibition ≥ 80%; p < 0.04) (Table 2). This decrease was also confirmed by direct observations (inverted optical microscopy) (data not shown). This multi-method approach makes it possible to be sure that there is no interference between lichen extracts and XTT, leading to false positives.
Additionally, microscopic observations performed at the end of anti-biofilm tests using trypan blue staining showed that yeasts growing as biofilm were still alive after treatment (all cells were colorless), suggesting a non-lethal effect of the active extracts. Thus, these preliminary observations and results suggest that active extracts may act thanks to a dispersant or removing action that would not disrupt the fungal cell membrane.
The anti-biofilm activity of the studied lichens is poorly documented and no bibliographic data reported anti-biofilm activity for the tested extracts. Thus, results obtained for the seven lichens whose extracts have demonstrated anti-maturation and anti-biofilm activities are innovative in this field of research.
2.5. Comparison of Chemical Profiles of Active and Inactive Extracts
Regarding the compounds in active and inactive extracts, some metabolites did not appear to be involved in the anti-maturation effect observed. Thus, the dibenzofurans placodiolic, pannaric, or didymic acids (predominant in Leprocaulon microscopicum, Lepraria membranacea, and Cladonia incrassate, respectively), the depsides atranorin and thamnolic acid (predominant in Pseudevernia furfuracea and Cetrelia olivetorum for atranorin, and predominant in Cladonia parasitica, C. squamosal, and Usnea florida for thamnolic acid), the depsides with aliphatic chains divaricatic and perlatolic acids (present in Neofuscellia pulla); the tridepsides gyrophoric acid and tenuiorin (predominant in Lasallia pustulata and Peltigera species), the depsidone norstictic acid (predominant in Pleurosticta acetabulum) or the aliphatic acid caperatic acid (predominant in Flavoparmelia caperata and Platismatia glauca) and rocellic acid (Lepraria membranacea), and the triterpene zeorin (present in Leprocaulon microscopicum) were reported in inactive extracts. Lichens with a chemical profile dominated by terpenoids, (in the genus Peltigera), were also mostly inactive.
Some compounds (such as usnic, fumarprotocetraric, protocetraric, salazinic, and squamatic acids), were present both in active and inactive extracts. Their role in the biological activity is more questionable. Focusing on the widespread dibenzofuran, usnic acid, a weak activity has been shown for lichens containing high proportions of this metabolite. This observation was confirmed by a HPLC dosage using a calibration curve with usnic acid (Supplemental Figure S2). Usnic acid represent 40% of the dried weight of the extract in Usnea florida and 20% of the dried weigh of the extract for Flavoparmelia caperata . This result suggested the poor implication of this compound against the development and maturation of Candida biofilms.
Finally, some compounds (stictic acid, evernic acid, parietin) were predominant only in active extracts (X. conspersa, E. prunastri, R. fastigiata, and X. parietina) suggesting their implication in the anti-maturation process of C. albicans biofilms (Supplemental Figure S1).
The extracts with the highest activity against both growing biofilms and 24 h old biofilms, E. prunastri and R. fastigiata, were dominated by the presence of the previously-mentioned evernic acid [29,30]. E. prunastri and evernic acid have already been studied for their antiproliferative and antimicrobial activities [31,32]. In a recent publication, the effect of evernic acid on bacterial biofilm has been evaluated and this depside has demonstrated a capacity to inhibit Pseudomonas aeruginosa quorum sensing systems .
Stictic acid, is a depsidone dominated the chemical composition of the extract of X. conspersa . Antioxidant, antimicrobial, and apoptotic effect have already been described for stictic acid but no anti-biofilm activity is reported [35,36]. We suggested here the possible interest of this compound against C. albicans biofilms.
The other Xanthoparmelia, X. tinctina, has a complex chemical composition dominated by usnic acid and the depsidone salazinic acid. Surprisingly, salazinic acid is also present in lichens without any activity suggested possible synergistic mechanism inside this extract.
Another depside, squamatic acid, whose structure is closely related to evernic acid, is associated to usnic acid in C. uncialis extract ,and could also be involved in anti-biofilm activities . The large proportion of (−)-usnic acid in this extract invites to distinguish the difference of activity between the two isomers. Studies reported activities of usnic acid against bacterial biofilms (Staphylococcus, Streptococcus, etc.) but also against fungal biofilms [37,38,39,40]. A recent study demonstrated that usnic acid exhibited a significant biofilm inhibition against azole-resistant and azole-sensitive C. albicans strains (71.08% and 87.84%, respectively). This effect would be mediated by oxidative and nitrosative stress, with a significant accumulation of intracellular and extracellular reactive oxygen species . Usnic acid also inhibited the yeast to hyphal switch and reduced the thickness of matured biofilms of C. albicans . Furthermore, it was able to reduce various sugars present in the exopolysaccharide layer. However, this compound does not appear to be effective against C. krusei biofilms and the effect is controversial against C. parapsilosis [38,42].
P. hymenina extract is constituted by a mixture of terpenoids and unidentified depsides and the role of each compound in the activity needs to be further established. The chemical profile of C. ramulosa, showed the presence of fumarprotocetraric acid along with another unidentified compound (Supplemental Figure S1).
Thus, this preliminary screening is a springboard towards additional investigations on lichen metabolites. Indeed, the pure compounds will be isolated in sufficient quantity from lichens and will be evaluated. If the activity against biofilms is not confirmed, synergistic effects and identification and isolation of minor compounds will be undertaken.
3.1. Phytochemical Analysis
3.1.1. Lichen Material
Lichens have mainly been collected from soil and trees in the countryside around Limoges city. Their identification was confirmed by lichenologists belonging to AFL (French Association of Lichenology). Voucher specimens were deposited at the herbarium of the faculty of pharmacy of Limoges. Place, date of collection, as well as reference numbers of the voucher specimens, are summarized in Supplemental Table S1.
3.1.2. Extraction of Lichen and Analytical Studies
The dried thalli of lichens (5 g) were extracted with acetone (10 mL, three times) at room temperature. After filtration, the acetone filtrates were concentrated under reduced pressure to give solid extracts.
TLCs were performed on pre-coated silica gel aluminium sheets (Kieselgel 60 F254, 0.20 mm, Merck KGaA, Darmstadt, Germany). Extracts were dissolved in acetone (at a concentration of 5 mg/mL) before being deposited on the TLC sheets and eluted in two system solvents: n-hexane–ethylether–HCOOH 130:80:20 and toluene–EtOAc–HCOOH, 70:20:5. The visualization of the plates was carried out under UV light (254 and 365 nm). Then TLCs were sprayed with the anisaldehyde sulfuric reagent followed by heating at 100 °C. This reagent leads to purple spots for dibenzofurans, red spots for depsides, yellow and orange spots for depsidones, and pink and blue spots for terpenes. The following standards have been used: atranorin; zeorin; tenuiorin, evernic, gyrophoric, thamnolic, squamatic, norstictic, fumarprotocetraric acid, protocetraric, salazinic, stictic, didymic, pannaric, placodiolic, usnic, rocellic, and caperatic acids. The standards have been previously isolated in our laboratory from various lichen species and identified on the basis of NMR and MS spectra.
HPLC analyses of the active extracts were performed on a Waters Alliance 2690 (Waters Corporation, Milford, MA, USA) using a reversed-phase Hibar® LiChrospher® 100 C-18 column (5 µm, 250 × 4 mm, Merck KGaA, Darmstadt, Germany ) and using a photodiode-array detector (Waters 996). The elution solvent MeOH–H2O–H3PO4 80:20:0.9 has been used on isocratic mode at a flow rate of 1 mL/min according to the protocol of Yoshimura et al. . Lichen extracts were prepared at 5 mg/mL in a mixture of methanol and DMSO (90:10).
3.2. Biological Activities
3.2.1. Minimal Inhibitory Concentration of Lichen Extracts
Stock solutions of lichen extracts were prepared in DMSO at 10 mg/mL and shaken. Their minimum inhibitory concentrations (MICs) were determined by a broth microdilution method in order to determine their antifungal activities (CLSI reference M27-A3 micromethod adapted protocol). The Candida albicans ATCC 3153 strain, purchased from the American Type Culture Collection, was used. Briefly, yeasts were first grown for 24 h on Sabouraud agar slants (Sanofi Diagnostics Pasteur, Marnes-la-Coquette, France) and C. albicans inocula were prepared by suspending yeasts in sterile physiological serum and adjusting to 0.5 MacFarland of absorbance. A one-thousandth dilution in RPMI (Roswell Park Memorial Institute)-MOPS (4-Morpholinepropanesulfonic acid) (Sigma, St. Louis, MO, USA) of this previous solution was made.
Serial two-fold dilutions of each stock solution were prepared in RPMI-MOPS in 96-well microtiter plates (Fisher Scientific, Illkirch, France) over the range 100 μg/mL to 0.048 μg/mL final (final DMSO concentrations did not exceed 2% of the overall volume in wells). The same volume per well of yeast culture was then added. Some wells were reserved for controls: non-treated yeasts (negative control); yeasts treated by DMSO 2%; and yeasts treated by fluconazole (positive control). The MICs were determined after incubation for 24 and 48 h at 37 °C without shaking. All tests were performed in duplicate in at least two separate experiments. Lichen extracts with a MIC less than 50 μg/mL were considered as potentially useful.
3.2.2. Anti-Biofilm Tests
The tests were performed using the stock solutions of lichen extracts previously prepared. Serial two-fold dilutions of each stock solution were prepared in Yeast Nitrogen Base medium (Difco, Detroit, MI, USA), supplemented with 50 mM glucose (Sigma, St. Louis, MO, USA) (YNB-Glc) over the final range 200 μg/mL to 0.097 μg/mL for the anti-maturation test or at 100, 50, and 10 μg/mL for the anti-biofilm test (final DMSO concentrations did not exceed 2% of the overall volume in wells).
As for MIC assay, C. albicans ATCC 3153 yeasts were first grown for 24 h on Sabouraud agar slants. Then, four loopfuls of this culture were carefully transferred to 30 mL of YNB-Glc and incubated overnight at 37 °C without shaking. Obtained blastospores were harvested, washed twice in 0.1 M phosphate-buffered saline (PBS, pH 7.2), and adjusted to 1 × 107 blastospores/mL in YNB-Glc.
Non-stimulated saliva collected from 12 healthy volunteers was pooled, altered with dithiothreitol (Sigma, St. Louis, MO, USA) (2.5 mmol/L), shaken on ice for 10 min, and centrifuged for 20 min at 3000× g and 4 °C (Cr3i centrifuge Jouan). The supernatant was diluted in three volumes of distilled water (25%), and filtered through a 0.45 μm membrane. This 25% sterile stock solution was stored at −80 °C.
Untreated 96-well tissue culture plates were filled with 200 μL of human saliva at 2%, obtained by dilution of the 25% sterile stock solution in distilled water, incubated for 1 h at 37 °C, and then completely aspirated; this pretreatment was done to encourage biofilm formation. Two-hundred microliters per well of yeast culture were then added. After 2 h of incubation at 37 °C for the anti-maturation test and 24 h of incubation at 37 °C for the anti-biofilm test, the non-adherent yeasts were removed by washing with PBS. Then, 250 μL of YNB-Glc and 50 μL of each dilution of lichen extracts were added to each well. Some wells were reserved for controls: non-treated yeasts (negative control) and yeasts treated by DMSO 2%. The plates were incubated for 24 h and/or 48 h at 37 °C. Then spent media and free-floating microorganisms were removed by aspiration. Wells were washed twice with PBS and observed under inverted optical microscope (IX51® inverted microscope, Olympus America Inc., Melville, NY, USA) prior to biofilm quantification using a previously described metabolic assay based on the reduction of a tetrazolium salt (XTT) [44,45]. Briefly, 300 mg/L XTT (Sigma) and 0.13 mM menadione (Sigma) were added to 200 μL of PBS in each well. Plates were incubated for 3 h at 37 °C without shaking, then gently agitated and XTT formazan was measured colorimetrically at 450 nm (microplate reader LP400; Sanofi Diagnostics Pasteur) in order to determine the concentration inhibiting 50% of biofilm development. Background formazan values were determined with plates containing PBS only or containing PBS, XTT, and menadione; these values did not exceed 0.005 absorbance units and were, therefore, considered not significant. All anti-maturation and anti-biofilm tests were performed in duplicate and sextuplicate, respectively, in at least two separate experiments.
Statistical analysis was conducted thanks to the Kruskal-wallis test to determine differences among the test groups .
3.2.3. CFU Counts and Trypan Blue Staining Assays
At the end of anti-biofilm tests, four wells were used to conduct CFU counts: adherent cells treated or not with the highest concentration of lichen extract were scraped; the obtained cells were resuspended in PBS and sowed twice on Sabouraud agar plates after the dilution process. Colonies were counted after 24 h of incubation at 37 °C and the inhibition percentages ± standard deviations (SD) of cultivable cells were determined. Statistical analysis was conducted thanks to the Wilcoxon test .
Cell viability was evaluated thanks to trypan blue (Sigma, St. Louis, MO, USA) staining using four other wells. Briefly, the diluted dye was added to the cells, treated or not, and adhered to the bottom of the wells and living (colorless) and dead (blue) cells were counted under a microscope. Assays were repeated in at least two separate experiments.
Among the 38 extracts evaluated, seven of them demonstrated anti-maturation and anti-biofilm activities against C. albicans with IC50_mat 48h and biof ≤100 µg/mL. E. prunastri and R. fastigiata were the most promising lichens (IC50_mat 48h < 4 µg/mL and IC50_biof < 10 µg/mL). They exert on the mature biofilm a dispersant or removing action that would not disrupt the fungal cell membrane. The activities (against both growing biofilms and 24 h old biofilms) of the seven promising extracts will have to be confirmed by studying a large panel of clinical strains in order to check that these activities are not strain-dependent. These results complete the few available data concerning anti-biofilm interests of lichen extracts. For the first time this study underlines the ability of seven lichen species from Limousin to slow down the maturation phase of C. albicans biofilms (which is very important to avoid yeast dispersion) and to reduce already-formed biofilms (which contributes to reducing the infectious reservoir). The chemical investigation and comparisons performed on chemical profiles of active and inactive extracts underline that depsides (evernic and squamatic acids) and depsidones (stictic acid) may be involved in the anti-biofilm activity. The lichen compounds should now be isolated to be further investigated for their activities and possible synergistic actions.
Supplementary materials are available online. Figures S1, S2 and Table S1.
This work was financially supported by PEPS ExoMod (CNRS, France). We are grateful to AFL members for the confirmation of lichen identification, to Pr J. Boustie for exchange of chemical standards and to S. Langeraar for revising the English text.
M.M. collected and identified lichens, and realized the extracts and their phytochemical analysis. L.D. performed the antifungal tests during her Master 2 degree. M.G. performed all other biological assays. M.M. and M.G. wrote the manuscript. L.M. supervised the phytochemical work and C.I. supervised the biological work. L.M. and C.I. participated to the corrections of final manuscript.
Conflicts of Interest
The authors declare no conflict of interest.
- Spribille, T.; Tuovinen, V.; Resl, P.; Vanderpool, D.; Wolinski, H.; Aime, M.C.; Schneider, K.; Stabentheiner, E.; Toome-Heller, M.; Thor, G.; et al. Basidiomycete yeasts in the cortex of ascomycete macrolichens. Science 2016, 353, 488–492. [Google Scholar] [CrossRef] [PubMed]
- Hays, S.G.; Patrick, W.G.; Ziesack, M.; Oxman, N.; Silver, P.A. Better together: Engineering and application of microbial symbioses. Curr. Opin. Biotechnol. 2015, 36, 40–49. [Google Scholar] [CrossRef] [PubMed]
- Garg, N.; Zeng, Y.; Edlund, A.; Melnik, A.V.; Sanchez, L.M.; Mohimani, H.; Gurevich, A.; Miao, V.; Schiffler, S.; Lim, Y.W.; et al. Spatial Molecular Architecture of the Microbial Community of a Peltigera Lichen. mSystems 2016, 1, e00139-16. [Google Scholar] [CrossRef] [PubMed]
- Zambare, V.P.; Christopher, L.P. Biopharmaceutical potential of lichens. Pharm. Biol. 2012, 50, 778–798. [Google Scholar] [CrossRef] [PubMed]
- Yuan, X. Lichen-like symbiosis 600 million years ago. Science 2005, 308, 1017–1020. [Google Scholar] [CrossRef] [PubMed]
- Underhill, D.M.; Iliev, I.D. The mycobiota: Interactions between commensal fungi and the host immune system. Nat. Rev. Immunol. 2014, 14, 405–416. [Google Scholar] [CrossRef] [PubMed]
- Nobile, C.J.; Johnson, A.D. Candida albicans Biofilms and Human Disease. Annu. Rev. Microbiol. 2015, 69, 71–92. [Google Scholar] [CrossRef] [PubMed]
- Pappas, P.G. Invasive Candidiasis. Infect. Dis. Clin. N. Am. 2006, 20, 485–506. [Google Scholar] [CrossRef] [PubMed]
- Wisplinghoff, H.; Ebbers, J.; Geurtz, L.; Stefanik, D.; Major, Y.; Edmond, M.B.; Wenzel, R.P.; Seifert, H. Nosocomial bloodstream infections due to Candida spp. in the USA: Species distribution, clinical features and antifungal susceptibilities. Int. J. Antimicrob. Agents 2014, 43, 78–81. [Google Scholar] [CrossRef] [PubMed]
- Campion, E.W.; Kullberg, B.J.; Arendrup, M.C. Invasive Candidiasis. N. Engl. J. Med. 2015, 373, 1445–1456. [Google Scholar] [CrossRef] [PubMed]
- Schelenz, S.; Abdallah, S.; Gray, G.; Stubbings, H.; Gow, I.; Baker, P.; Hunter, P.R. Epidemiology of oral yeast colonization and infection in patients with hematological malignancies, head neck and solid tumors: Oral candidiasis in cancer patients. J. Oral Pathol. Med. 2011, 40, 83–89. [Google Scholar] [CrossRef] [PubMed]
- Lortholary, O.; Petrikkos, G.; Akova, M.; Arendrup, M.C.; Arikan-Akdagli, S.; Bassetti, M.; Bille, J.; Calandra, T.; Castagnola, E.; Cornely, O.A.; et al. ESCMID* *This guideline was presented in part at ECCMID 2011. European Society for Clinical Microbiology and Infectious Diseases. Guideline for the diagnosis and management of Candida diseases 2012: Patients with HIV infection or AIDS. Clin. Microbiol. Infect. 2012, 18, 68–77. [Google Scholar] [CrossRef] [PubMed]
- Odds, F.C. Candida and Candidosis, 2nd ed.; Tindall: London, UK, 1988. [Google Scholar]
- Radford, D.R.; Challacombe, S.; Walter, J.D. Denture plaque and adherence of Candida albicans to denture-base materials in vivo and in vitro. Crit. Rev. Oral Biol. Med. 1999, 10, 99–116. [Google Scholar] [CrossRef] [PubMed]
- Bürgers, R.; Hahnel, S.; Reichert, T.E.; Rosentritt, M.; Behr, M.; Gerlach, T.; Handel, G.; Gosau, M. Adhesion of Candida albicans to various dental implant surfaces and the influence of salivary pellicle proteins. Acta Biomater. 2010, 6, 2307–2313. [Google Scholar] [CrossRef] [PubMed]
- Soustre, J. Caspofungin modulates in vitro adherence of Candida albicans to plastic coated with extracellular matrix proteins. J. Antimicrob. Chemother. 2004, 53, 522–525. [Google Scholar] [CrossRef] [PubMed]
- Chandra, J.; Kuhn, D.M.; Mukherjee, P.K.; Hoyer, L.L.; McCormick, T.; Ghannoum, M.A. Biofilm Formation by the Fungal Pathogen Candida albicans: Development, Architecture, and Drug Resistance. J. Bacteriol. 2001, 183, 5385–5394. [Google Scholar] [CrossRef] [PubMed]
- Donlan, R.M.; Costerton, J.W. Biofilms: Survival mechanisms of clinically relevant microorganisms. Clin. Microbiol. Rev. 2002, 15, 167–193. [Google Scholar] [CrossRef] [PubMed]
- Shahzad, M.; Sherry, L.; Rajendran, R.; Edwards, C.A.; Combet, E.; Ramage, G. Utilising polyphenols for the clinical management of Candida albicans biofilms. Int. J. Antimicrob. Agents 2014, 44, 269–273. [Google Scholar] [CrossRef] [PubMed]
- Tsang, P.W.-K.; Bandara, H.M.H.N.; Fong, W.-P. Purpurin Suppresses Candida albicans Biofilm Formation and Hyphal Development. PLoS ONE 2012, 7, e50866. [Google Scholar] [CrossRef] [PubMed]
- Mitrović, T.; Stamenković, S.; Cvetković, V.; Tošić, S.; Stanković, M.; Radojević, I.; Stefanović, O.; Čomić, L.; Đačić, D.; Ćurčić, M.; et al. Antioxidant, Antimicrobial and Antiproliferative Activities of Five Lichen Species. Int. J. Mol. Sci. 2011, 12, 5428–5448. [Google Scholar] [CrossRef] [PubMed]
- Chang, W.; Li, Y.; Zhang, L.; Cheng, A.; Liu, Y.; Lou, H. Retigeric acid B enhances the efficacy of azoles combating the virulence and biofilm formation of Candida albicans. Biol. Pharm. Bull. 2012, 35, 1794–1801. [Google Scholar] [CrossRef] [PubMed]
- Elix, J.A. A Catalogue of Standardized Chromatographic Data and Biosynthetic Relationships for Lichen Substances, 3rd ed.; Published by the Author; Australian National University: Canberra, Australia, 2014. [Google Scholar]
- Orange, A.; James, P.W.; White, F.J. Microchemical Methods for the Identification of Lichens; British Lichen Society: London, UK, 2001. [Google Scholar]
- Identification des Espèces de Lichen du Monde. Available online: http://liaslight.lias.net/Identification/Navikey/World/fr_FR/index.html (accessed on 13 March 2017).
- Studzińska-Sroka, E.; Hołderna-Kędzia, E.; Galanty, A.; Bylka, W.; Kacprzak, K.; Ćwiklińska, K. In vitro antimicrobial activity of extracts and compounds isolated from Cladonia uncialis. Nat. Prod. Res. 2015, 29, 2302–2307. [Google Scholar] [CrossRef] [PubMed]
- Ranković, B.; Misić, M.; Sukdolak, S. Antimicrobial activity of extracts of the lichens Cladonia furcata, Parmelia caperata, Parmelia pertusa, Hypogymnia physodes and Umbilicaria polyphylla. Br. J. Biomed. Sci. 2007, 64, 143–148. [Google Scholar] [CrossRef] [PubMed]
- Dieu, A. Recherche de Molécules Antimicrobiennes D’origine Lichénique. Etude de Trois Lichens et Approche Synthétique de Deux Composés Actifs. Ph.D. Thesis, University of Limoges, Limoges, France, 1 June 2015. [Google Scholar]
- Culberson, C.F. The lichen substances of the genus Evernia. Phytochemistry 1963, 2, 335–340. [Google Scholar] [CrossRef]
- Ristic, S.; Rankovic, B.; Kosanić, M.; Stamenkovic, S.; Stanojković, T.; Sovrlić, M.; Manojlović, N. Biopharmaceutical Potential of Two Ramalina Lichens and their Metabolites. Curr. Pharm. Biotechnol. 2016, 17, 651–658. [Google Scholar] [CrossRef] [PubMed]
- Kosanić, M.; Manojlović, N.; Janković, S.; Stanojković, T.; Ranković, B. Evernia prunastri and Pseudoevernia furfuraceae lichens and their major metabolites as antioxidant, antimicrobial and anticancer agents. Food Chem. Toxicol. 2013, 53, 112–118. [Google Scholar] [CrossRef] [PubMed]
- Shcherbakova, A.; Nyugen, L.; Koptina, A.; Backlund, A.; Shurgin, A.; Romanov, E.; Ulrich-Merzenich, G. Screening of compounds of Evernia prunastri (L.) for their antiproliferative activity in glioblastoma cells. Planta Med. 2016, 81, S1–S381. [Google Scholar] [CrossRef]
- Gökalsın, B.; Sesal, N.C. Lichen secondary metabolite evernic acid as potential quorum sensing inhibitor against Pseudomonas aeruginosa. World J. Microbiol. Biotechnol. 2016, 32, 150. [Google Scholar] [CrossRef] [PubMed]
- Amo de Paz, G.; Raggio, J.; Gómez-Serranillos, M.P.; Palomino, O.M.; González-Burgos, E.; Carretero, M.E.; Crespo, A. HPLC isolation of antioxidant constituents from Xanthoparmelia spp. J. Pharm. Biomed. Anal. 2010, 53, 165–171. [Google Scholar] [CrossRef] [PubMed]
- Oran, S.; Sahin, S.; Sahinturk, P.; Ozturk, S.; Demir, C. Antioxidant and Antimicrobial Potential, and HPLC Analysis of Stictic and Usnic Acids of Three Usnea Species from Uludag Mountain (Bursa, Turkey). Iran. J. Pharm. Res. 2016, 15, 527. [Google Scholar] [PubMed]
- Correché, E.R.; Enriz, R.D.; Piovano, M.; Garbarino, J.; Gómez-Lechón, M.J. Cytotoxic and apoptotic effects on hepatocytes of secondary metabolites obtained from lichens. Altern. Lab. Anim. ATLA 2004, 32, 605–615. [Google Scholar] [PubMed]
- Pompilio, A.; Riviello, A.; Crocetta, V.; Di Giuseppe, F.; Pomponio, S.; Sulpizio, M.; Di Ilio, C.; Angelucci, S.; Barone, L.; Di Giulio, A.; et al. Evaluation of antibacterial and antibiofilm mechanisms by usnic acid against methicillin-resistant Staphylococcus aureus. Future Microbiol. 2016, 11, 1315–1338. [Google Scholar] [CrossRef] [PubMed]
- Kvasnickova, E.; Matatkova, O.; Cejkova, A.; Masak, J. Evaluation of baicalein, chitosan and usnic acid effect on Candida parapsilosis and Candida krusei biofilm using a Cellavista device. J. Microbiol. Methods 2015, 118, 106–112. [Google Scholar] [CrossRef] [PubMed]
- Nithyanand, P.; Beema Shafreen, R.M.; Muthamil, S.; Karutha Pandian, S. Usnic acid inhibits biofilm formation and virulent morphological traits of Candida albicans. Microbiol. Res. 2015, 179, 20–28. [Google Scholar] [CrossRef] [PubMed]
- Martinelli, A.; Bakry, A.; D’Ilario, L.; Francolini, I.; Piozzi, A.; Taresco, V. Release behavior and antibiofilm activity of usnic acid-loaded carboxylated poly(l-lactide) microparticles. Eur. J. Pharm. Biopharm. 2014, 88, 415–423. [Google Scholar] [CrossRef] [PubMed]
- Peralta, M.; da Silva, M.; Ortega, M.; Cabrera, J.; Paraje, M. Usnic acid activity on oxidative and nitrosative stress of azole-resistant Candida albicans biofilm. Planta Med. 2016, 83, 326–333. [Google Scholar] [CrossRef] [PubMed]
- Pires, R.H.; Lucarini, R.; Mendes-Giannini, M.J.S. Effect of Usnic Acid on Candida orthopsilosis and C. parapsilosis. Antimicrob. Agents Chemother. 2012, 56, 595–597. [Google Scholar] [CrossRef] [PubMed]
- Yoshimura, I.; Kinoshita, Y.; Yamamoto, Y.; Huneck, S.; Yamada, Y. Analysis of secondary metabolites from Lichen by high performance liquid chromatography with a photodiode array detector. Phytochem. Anal. 1994, 5, 197–205. [Google Scholar] [CrossRef]
- Cocuaud, C. Anti-metabolic activity of caspofungin against Candida albicans and Candida parapsilosis biofilms. J. Antimicrob. Chemother. 2005, 56, 507–512. [Google Scholar] [CrossRef] [PubMed]
- Dalleau, S.; Cateau, E.; Bergès, T.; Berjeaud, J.-M.; Imbert, C. In vitro activity of terpenes against Candida biofilms. Int. J. Antimicrob. Agents 2008, 31, 572–576. [Google Scholar] [CrossRef] [PubMed]
- Tableau des Tests Statistiques D’hypothèse. Available online: https://marne.u707.jussieu.fr/biostatgv/?module=tests (accessed on 13 March 2017).
Sample Availability: Not available.
Table 1. Lichen species, extraction rates, and chemical composition of the lichens reported in the literature data and the main metabolites present in acetone extracts (determined by TLC and/or HPLC). Nd = non determined.
|No.||Lichens||% Yield||Theoretical Chemical Composition of Lichen ||Main Metabolite(s) Present in the Acetone Extracts|
|2||Bryoria fuscescens||3.0||Cetraric acid; fumarprotocetraric acid||Fumarprotocetraric acid|
|3||Cetraria islandica||0.8||Protocetraric acid; protolichesterinic acid; fumarprotocetraric acid||Fumarprotocetraric acid|
|4||Cetrelia olivetorum||6.0||Atranorin; perlatolic acid; imbricaric acid and derivatives; fatty acids||Atranorin|
|5||Cladonia fimbriata||1.0||Atranorin; convirensic acid; fumarprotocetraric and protocetraric acids||Atranorin Fumarprotocetraric acid|
|6||Cladonia furcata||0.8||Atranorin; cetraric and fumarprotocetraric acids||Fumarprotocetraric acid|
|7||Cladonia glauca||1.9||Squamatic acid||Squamatic acid|
|8||Cladonia gracilis||1.6||Atranorin; fumarprotocetraric acid; quaesic acid||Fumarprotocetraric acid|
|9||Cladonia incrassata||5.5||(−)-Usnic acid; squamatic acid; didymic, subdidymic and condidymic acids||Didymic acid; squamatic acid|
|10||Cladonia parasitica||1.9||Barbatic acid; thamnolic acid and derivatives||Thamnolic acid|
|11||Cladonia ramulosa||4.6||Fumarprotocetraric acid and derivatives; protocetraric and sekikaic acids||Unidentified depside fumarprotocetraric acid|
|12||Cladonia rangiferina||1.5||Atranorin and fumarprotocetraric acid||Atranorin; fumarprotocetraric acid|
|13||Cladonia scabriuscula||2.0||Atranorin; fumarprotocetraric and protocetraric acids||Fumarprotocetraric acid|
|14||Cladonia squamosa||2.6||Barbatic acid; squamatic acid; thamnolic acid and derivatives; triterpenoids||Squamatic acid; thamnolic acid|
|15||Cladonia subulata||4.4||Fumarprotocetraric and quaesitic acids||Fumarprotocetraric acid|
|16||Cladonia uncialis||1.9||Squamatic acid and (−)-usnic acid||Squamatic acid and usnic acid|
|17||Evernia prunastri||7.5||Atranorin; chloroatranorin; evernic acid and (+)-usnic acid||Evernic and usnic acids|
|18||Flavoparmelia caperata||6.2||Atranorin; caperatic acid; protocetraric acid and (+)-usnic acid||Caperatic acid; protocetraric acid and usnic acid|
|19||Hypogymnia physodes||8.7||Atranorin; chloroatranorin; physodalic acid; physodic acid and derivatives; protocetraric acid||Fumarprotocetraric and other unidentified depsides or depsidones|
|20||Lasallia pustulata||5.8||Gyrophoric acid||Gyrophoric acid|
|21||Lepraria membranacea||5.6||Pannaric acid||Pannaric and rocellic acids|
|22||Leprocaulon microscopicum||8.4||Placodiolic acid; (−)-usnic acid; zeorin||Usnic acid; placodiolic acid and zeorin|
|24||Neofuscellia pulla||2.1||Divaricatic acid; perlatolic acid; stenosporic acid and derivatives; gyrophoric acid||Divaricatic and perlatolic acids|
|25||Parmelia saxatilis||10.1||Atranorin; chloroatranorin; salazinic and consalazinic acids||Salazinic acid|
|26||Parmelia sulcata||2.9||Atranorin; chloroatranorin; salazinic and derivatives; lobaric acid||Salazinic acid|
|27||Platismatia glauca||10.5||Atranorin; caperatic acid and pseudoplacodiolic acid||Atranorin; caperatic acid|
|29||Peltigera horizontalis||0.7||Terpenoids||Tenuiorin and terpenoids|
|30||Peltigera hymenina||1.7||Gyrophoric acid and terpenoids||Unidentified depsides and terpenoids|
|32||Pleurosticta acetabulum||1.9||Norstictic acid; connorstictic acid and terpenoids||Norstictic acid Terpenoids|
|34||Ramalina fastigiata||3.5||Evernic acid and (+)-usnic acid||Evernic and usnic acids|
|35||Usnea florida||5.4||Alectorialic, bourgeanic, diffractaic acids; squamatic, thamnolic and (+)-usnic acids||Usnic and thamnolic acids|
|36||Xanthoparmelia conspersa||4.8||Stictic acid and derivatives; (+)-usnic acid; hyposalazinic and menegazziaic acids||Stictic and usnic acids|
|37||Xanthoparmelia tinctina||3.3||Salazinic acid; norstictic acid; protocetraric acid and (+)-usnic acid||Salazinic and usnic acids|
Table 2. Lichen extracts effective against the maturation phase of Candida albicans biofilms (concentration < 200 µg/mL at 24 h or 48 h). Kruskal-wallis test: p < 0.03, in duplicate, n = 2; Only extracts having demonstrated an anti-maturation activity (IC50_mat 48 h ≤ 50 µg/mL) have been selected and tested against pre-formed biofilms with an age of 24 h. This anti-biofilm activity was evaluated after a 48 h incubation, Kruskal-wallis test: p < 0.0002, in sextuplicate n = 2; colony-forming unit (CFU) counts: Wilcoxon test: p < 0.04, in duplicate, n = 2; SD = standard deviation.
|No.||Lichens||Anti-Maturation Activity IC50 (µg/mL)||Anti-Biofilm Activity|
|24 h||48 h||IC50 (µg/mL)||CFU Counts Inhibition (% ± SD)|
|11||Cladonia ramulosa||≥200||50||50||85 ± 16|
|16||Cladonia uncialis||≥200||25||<10||90 ± 14|
|17||Evernia prunastri||25||1.56||<10||86 ± 11|
|30||Peltigera hymenina||50||12.5||50||80 ± 22|
|34||Ramalina fastigiata||25||3.125||<10||82 ± 17|
|36||Xanthoparmelia conspersa||100||25||<10||94 ± 5|
|37||Xanthoparmelia tinctina||≥200||6.25||100||82 ± 14|
© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).